相似文献
1
Comment on 'Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank' by Lim et al.
J Cachexia Sarcopenia Muscle. 2025;16(3):e13854. doi: 10.1002/jcsm.13854.
2
Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank.
J Cachexia Sarcopenia Muscle. 2025 Apr;16(2):e13757. doi: 10.1002/jcsm.13757.
3
Associations between skeletal muscle strength and chronic kidney disease in patients with MASLD.
Commun Med (Lond). 2025 Apr 16;5(1):118. doi: 10.1038/s43856-025-00821-x.
4
Association between triglyceride-glucose (TyG) related indices and cardiovascular diseases and mortality among individuals with metabolic dysfunction-associated steatotic liver disease: a cohort study of UK Biobank.
Cardiovasc Diabetol. 2025 Jan 13;24(1):12. doi: 10.1186/s12933-024-02572-w.
5
Lower creatinine to cystatin C ratio is associated with an increased risk of MASLD: A cross-sectional and prospective study of 368,634 UK Biobank participants.
Clin Endocrinol (Oxf). 2024 Feb;100(2):116-123. doi: 10.1111/cen.14990. Epub 2023 Dec 26.
6
Correspondence on 'Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank' by Raisi-Estabragh .
Heart. 2023 Jan 2. doi: 10.1136/heartjnl-2022-322132.
7
Exploring the nexus between hypothyroidism and metabolic dysfunction-associated steatotic liver disease: a UK biobank cohort study.
Sci Rep. 2025 Feb 25;15(1):6692. doi: 10.1038/s41598-025-91221-7.
8
Joint associations of handgrip strength and physical activity with incident cardiovascular disease and overall mortality in the UK Biobank.
Clin Nutr. 2024 Dec;43(12):218-224. doi: 10.1016/j.clnu.2024.10.022. Epub 2024 Oct 19.
9
A high reticulocyte count is a risk factor for the onset of metabolic dysfunction-associated steatotic liver disease: Cross-sectional and prospective studies of data of 310,091 individuals from the UK Biobank.
Front Pharmacol. 2024 Jul 1;15:1281095. doi: 10.3389/fphar.2024.1281095. eCollection 2024.
10
Association of handgrip strength and/or walking pace with incident chronic kidney disease: A UK biobank observational study.
J Cachexia Sarcopenia Muscle. 2023 Apr;14(2):805-814. doi: 10.1002/jcsm.13180. Epub 2023 Jan 28.
本文引用的文献
1
Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank.
J Cachexia Sarcopenia Muscle. 2025 Apr;16(2):e13757. doi: 10.1002/jcsm.13757.
2
Modified FIB-4 Index in Type 2 Diabetes Mellitus with Steatosis: A Non-Linear Predictive Model for Advanced Hepatic Fibrosis.
Diagnostics (Basel). 2024 Nov 8;14(22):2500. doi: 10.3390/diagnostics14222500.
3
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7.
4
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies.
Pharmacol Rev. 2024 May 2;76(3):454-499. doi: 10.1124/pharmrev.123.001087.
5
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
Gut. 2024 Mar 7;73(4):691-702. doi: 10.1136/gutjnl-2023-330595.
6
Assessment of causal associations between handgrip strength and cardiovascular diseases: A two sample mendelian randomization study.
Front Cardiovasc Med. 2022 Aug 4;9:930077. doi: 10.3389/fcvm.2022.930077. eCollection 2022.
7
Limitations of non-invasive tests for assessment of liver fibrosis.
JHEP Rep. 2020 Jan 20;2(2):100067. doi: 10.1016/j.jhepr.2020.100067. eCollection 2020 Apr.
Zotero 插件